References
- Valenzuela RM, Rai R, Kirk BH, et al. An estimation of the risk of pseudotumor cerebri among users of the levonorgestrel intrauterine device. Neuro-Ophthalmology. 2017;41(4):192–197. doi:10.1080/01658107.2017.1304425.
- Ball AK, Clarke CE. Idiopathic intracranial hypertension. Lancet Neurol. 2006;5(5):433–442. doi:10.1016/S1474-4422(06)70442-2.
- Lindh I, Skjeldestad FE, Gemzell-Danielsson K, et al. Contraceptive use in the Nordic countries. Acta Obstet Gynecol Scand. 2017;96(1):19–28. doi:10.1111/aogs.2017.96.issue-1.
- Cibula D. Women’s contraceptive practices and sexual behaviour in Europe. Eur J Contraception Reprod Health Care. 2008;13(4):362–375. doi:10.1080/13625180802511541.
- Daniels K, Daugherty J, Jones J, Mosher W. Current contraceptive use and variation by selected characteristics among women aged 15–44: United States, 2011–2013. Natl Health Stat Report. 2015;10(86):1–14.
- Boulet SL, D’Angelo DV, Morrow B, et al. Contraceptive use among nonpregnant and postpartum women at risk for unintended pregnancy, and female high school students, in the context of Zika Preparedness – United States, 2011–2013 and 2015. MMWR Morb Mortal Wkly Rep. 2016 Aug 05;65(30):780–787. doi:10.15585/mmwr.mm6530e2.
- Sanders JN, Turok DK, Gawron LM, Law A, Wen L, Lynen R. Two-year continuation of intrauterine devices and contraceptive implants in a mixed-payer setting: a retrospective review. Am J Obstet Gynecol. 2017;216(6):590.e1–e8. doi:10.1016/j.ajog.2017.02.003.